Liquidia (NASDAQ:LQDA) CEO Roger Jeffs Sells 32,744 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) CEO Roger Jeffs sold 32,744 shares of the firm’s stock in a transaction on Monday, October 12th. The shares were sold at an average price of $28.48, for a total value of $932,549.12. Following the transaction, the chief executive officer owned 1,125,848 shares of the company’s stock, valued at $32,064,151.04. The trade was a 2.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Stock Down 3.1%

Shares of LQDA traded down $0.86 during trading hours on Tuesday, hitting $26.81. The company had a trading volume of 3,092,611 shares, compared to its average volume of 5,078,983. The stock has a market capitalization of $2.40 billion, a price-to-earnings ratio of 20.20 and a beta of 0.61. The firm has a fifty day moving average price of $63.40 and a 200-day moving average price of $61.76. Liquidia Corporation has a 52-week low of $21.94 and a 52-week high of $93.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). The firm had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The business’s revenue for the quarter was up 1842.1% compared to the same quarter last year. During the same period last year, the company posted ($0.49) earnings per share. On average, equities research analysts forecast that Liquidia Corporation will post 2.05 EPS for the current fiscal year.

Hedge Funds Weigh In On Liquidia

A number of hedge funds have recently bought and sold shares of the business. Bank of America Corp DE boosted its holdings in shares of Liquidia by 18.7% during the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after acquiring an additional 360,372 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Liquidia during the second quarter valued at approximately $29,694,000. Eversept Partners LP lifted its position in Liquidia by 33.0% during the first quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock valued at $25,565,000 after purchasing an additional 167,949 shares during the period. Seven Fleet Capital Management LP lifted its position in Liquidia by 25.2% during the second quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock valued at $20,459,000 after purchasing an additional 51,727 shares during the period. Finally, Pale Fire Capital SE lifted its position in Liquidia by 2.4% during the first quarter. Pale Fire Capital SE now owns 388,377 shares of the company’s stock valued at $14,657,000 after purchasing an additional 8,985 shares during the period. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Key Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reached a global settlement with United Therapeutics that resolves all six pending lawsuits and allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH). Eliminating years of patent, antitrust and trade-secret litigation reduces regulatory and commercial uncertainty. Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were $222.7 million, while cash and cash equivalents stood at $396.1 million at September 30. Management said it expects to fund the settlement and planned clinical programs from cash and ongoing sales without additional financing. The company also plans to continue developing YUTREPIA and L606.
• Neutral Sentiment: Multiple executives and insiders—including the CEO, CFO, CAO and general counsel—sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales reduced individual holdings but were not discretionary open-market transactions, making them a limited standalone signal of management confidence. Liquidia insider sale filing
• Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million: $175 million within 30 business days, $145.4 million in installments during 2027 and $60.3 million related to the antitrust litigation. The outflows could materially reduce its cash cushion and constrain investment, even though management expects to rebuild cash through YUTREPIA sales.
• Negative Sentiment: The company agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label, limiting the product’s addressable market. Liquidia also ended promotion of Treprostinil Injection, eliminating associated commercial revenue opportunities.
• Negative Sentiment: Recent insider activity remains heavily tilted toward selling—106 sales versus one purchase over six months—and a report highlighted a chairman’s share sale. Separately, a law firm announced an investor investigation related to disclosure of YUTREPIA litigation risks, adding potential reputational and legal uncertainty. Liquidia Negatively Rated Stock Pick of the Week

Analyst Ratings Changes

Several research analysts have recently issued reports on LQDA shares. Wedbush set a $58.00 target price on shares of Liquidia in a research note on Friday, October 2nd. BTIG Research lowered shares of Liquidia from a “buy” rating to a “neutral” rating in a report on Thursday, October 1st. Citigroup restated a “neutral” rating on shares of Liquidia in a report on Thursday, October 1st. Wall Street Zen cut Liquidia from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Finally, Weiss Ratings upgraded Liquidia from a “sell (d-)” rating to a “hold (c)” rating in a research note on Tuesday, September 22nd. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $83.69.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).